Radiation Shield Technologies Offers Patented Demron Apparel Providing Healthcare Workers and First Responders Unique Anti-Coronavirus Protection

“The standard gear worn by healthcare workers and first responders is ineffective at preventing transmission of the Coronavirus,” said Ronald DeMeo, M.D., CEO of Radiation Shield Technologies, the surgeon who developed the technology.

Demron provides the highest protection that cannot be found anywhere else. With this deadly virus posing an increased risk to those caring for the afflicted as well as the general public, it is critical for healthcare workers and first responders to wear the latest gear offering the highest protection.”

Dr. DeMeo received global news attention in 2011 when he recognized that emergency responders in Japan lacked proper gear while working to contain the country’s worst nuclear crisis since 1945. His Miami-based company then donated Demron full-body nuclear radiation protection suits to protect power plant workers and rescue teams. Similarly, Dr. DeMeo is now issuing a call-to-action to help ensure American healthcare workers and first responders utilize the appropriate gear to minimize Coronavirus contamination risk.

In addition to face masks that provide the highest level of protection against disease transmission, the Demron suits have patented thermal conductive capabilities that enable health-care workers suits to be externally monitored for the onset of fever, one of the first signs of the disease.

Additionally, Coronavirus-infected patients can also be monitored and externally cooled when infection transportation chambers are lined with the Demron fabric. Ongoing testing in this area is being carried out by Dipl. Eng. Pavel Castulik, Ph.D., at the Research Centre for Toxic Compounds in the Environment, Masaryk University, Czech Republic.

Demron, manufactured solely by RST, is the world’s first and only CBRN fabric that provides chemical, biological, radiological, and nuclear protection, while also enabling external temperature monitoring.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”